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Abstract
Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson’s disease dementia, affects over a
million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic
treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features, are limited
with only two drugs (cholinesterase inhibitors) currently approved by regulatory agencies for dementia in LBD.
Clinical trials represent a top research priority, but there are many challenges in the development and
implementation of trials in LBD. To address these issues and advance the field of clinical trials in the LBDs, the Lewy
Body Dementia Association formed an Industry Advisory Council (LBDA IAC), in addition to its Research Center of
Excellence program. The LBDA IAC comprises a diverse and collaborative group of experts from academic medical
centers, pharmaceutical industries, and the patient advocacy foundation. The inaugural LBDA IAC meeting, held in
June 2019, aimed to bring together this group, along with representatives from regulatory agencies, to address the
topic of optimizing the landscape of LBD clinical trials. This review highlights the formation of the LBDA IAC,
current state of LBD clinical trials, and challenges and opportunities in the field regarding trial design, study
populations, diagnostic criteria, and biomarker utilization. Current gaps include a lack of standardized clinical
assessment tools and evidence-based management strategies for LBD as well as difficulty and controversy in
diagnosing LBD. Challenges in LBD clinical trials include the heterogeneity of LBD pathology and symptomatology,
limited understanding of the trajectory of LBD cognitive and core features, absence of LBD-specific outcome
measures, and lack of established standardized biologic, imaging, or genetic biomarkers that may inform study
design. Demands of study participation (e.g., travel, duration, and frequency of study visits) may also pose
challenges and impact trial enrollment, retention, and outcomes. There are opportunities to improve the landscape
of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies,
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developing and validating outcome measures in LBD, engaging the patient community to assess research needs
and priorities, and incorporating biomarker and genotype profiling in study design.
Keywords: Biomarker, Clinical trial readiness, Dementia, Lewy bodies, Neuropsychology, Outcome measure,
Parkinson’s disease, Parkinsonism, Primary endpoint, Randomized controlled trial
Introduction
Lewy body dementia (LBD), comprised of dementia with
Lewy bodies (DLB) and Parkinson’s disease dementia
(PDD), affects approximately 1.4 million in the USA and
carries substantial public health impact [1, 2]. Currently
available symptomatic treatments for LBD vary in their
effectiveness and symptom target (i.e., cognitive impair-
ment, parkinsonism, psychosis, among others). Disease-
modifying and curative treatments are lacking. Clinical
trials for LBD are prioritized in the Alzheimer’s Disease
(AD)-Related Dementia (ADRD) Summit recommenda-
tions [3], but randomized clinical trials in LBD are few,
particularly compared to AD and Parkinson’s disease
(PD) without dementia [4, 5]. In order to advance the
field of LBD clinical trials, the Lewy Body Dementia As-
sociation (LBDA) developed a Research Centers of Ex-
cellence (RCOE) program in 2017, bringing together
expert clinicians and researchers across the USA with a
goal of becoming a clinical trials-ready network [6]. In
2019, the LBDA launched the Industry Advisory Council
(IAC) to provide a collaborative forum for discussion
among LBD experts, pharmaceutical industries, govern-
mental agencies, and the nonprofit LBDA to address
challenges and opportunities for LBD clinical trials. The
inaugural LBDA IAC meeting, held in June 2019, fo-
cused on key gaps and challenges in clinical trial design
and implementation in LBD. In this review, we discuss
the formation of the IAC, current state of LBD clinical
trials, and challenges and opportunities for optimizing
future clinical trials in LBD.
The need for partnerships and formation of the
LBDA IAC
Over the years, partnerships have developed among aca-
demic medical experts, patient advocacy groups,
pharmaceutical industries, and government bodies for
neurological and other diseases to address clinical and
research challenges. These collaborations have increased
awareness and diagnosis of the condition, improved ac-
cess to expert care, fostered interest for drug develop-
ment, and promoted clinical trial site readiness, all
critically important for increasing the likelihood of re-
cruitment and completion of clinical trials [7, 8]. These
partnerships may help reduce barriers in clinical re-
search such as shortening the long latency between drug
development and Food and Drug Administration (FDA)
approval, reducing the frequency of failed drug trials,
and potentially lessening the economic investment for
drug development [9]. As such, the LBDA formed an In-
dustry Advisory Council including invited members
from the RCOE network and Scientific Advisory Council
with clinical and research expertise in movement disor-
ders neurology, cognitive neurology, and neuropsych-
ology; pharmaceutical industries known to be currently
sponsoring or considering phase 2 or 3 clinical trials for
LBD; governmental agencies; and the LBDA foundation.
Diagnostic criteria and standards of care for LBD
LBD remains underdiagnosed or misdiagnosed, which
can delay appropriate clinical management and presents
challenges for LBD clinical trials. Difficulty in symptom
recognition, fluctuations in cognitive and functional
presentations, and differences in specialty access and
evaluations across healthcare systems contribute to these
challenges [10–12]. The DLB diagnostic criteria, revised
in 2017, define essential cognitive and core clinical fea-
tures and provide a framework to incorporate indicative
and supportive biomarkers of diagnosis [13]. The clinical
diagnostic criteria for PDD, published in 2007, include
features that distinguish dementia in the context of
established PD from AD or other dementias [14]. Both
DLB and PDD diagnoses are listed in the Diagnostic and
Statistical Manual of Mental Disorders (DSM)-5 as
major neurocognitive disorders [15]. Challenges and
controversy, however, remain in dividing LBD into DLB
and PDD given overlapping clinical symptoms,
biomarker findings, and underlying pathology, with the
“1-year” rule being a primary distinguishing factor. In
addition, criteria for mild cognitive impairment (MCI) in
PD and in DLB have been proposed [16, 17].
Additional tools have been developed to assist with
diagnosing and characterizing DLB since past diagnostic
criteria historically have had variable sensitivity in clin-
ical practice (12–88%) [18]. These tools include the
Lewy Body Composite Risk Score (LBCRS) [18], LBDA’s
diagnostic symptom checklist [19], National Alzheimer’s
Coordinating Center (NACC) DLB module [20], and
DIAMOND-Lewy Toolkit [10, 21]. The LBCRS, a rela-
tively short questionnaire and validated in a dementia
population, discriminates between DLB and AD and be-
tween MCI in these two groups. The LBDA checklist
provides a symptom list that people diagnosed with LBD
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or their caregivers can bring to a physician and a sum-
mary of DLB criteria. The NACC DLB module, devel-
oped in 2016 to accompany the Uniform Data Set used
in NIA AD Centers, aims to better characterize LBD
with a standardized clinical and cognitive battery. The
DIAMOND-Lewy Toolkit was developed in the UK to
assist with diagnosing DLB in clinical practice and uses
brief assessments deemed feasible by dementia and PD
clinicians. Harmonizing clinical assessment tools and ap-
plication of diagnostic criteria across DLB and PDD co-
horts in observational studies and across international
clinical and research efforts remains a priority and is
critical to LBD clinical trials.
At present, there is no consensus for a standard of
care for LBD, and evidence-based strategies are limited.
The UK DIAMOND-Lewy Management Toolkit pro-
vides clinicians with a management overview, symptom
management summaries, and reference guide, and sev-
eral recent reviews highlight management strategies
[22–25]. Regularly updated evidence-based reviews are
available for PD motor and non-motor symptoms, but
are lacking in LBD, especially for DLB [26]. Medications
for dementia have been studied in several double-blind,
placebo-controlled studies for LBD, with donepezil ap-
proved for DLB in Japan and rivastigmine approved for
PDD in the USA and European Union. Clinical care of
LBD is complex due to a wide range of symptoms (cog-
nitive impairment/dementia, parkinsonism, mood disor-
ders, psychosis, apathy, autonomic dysfunction, sleep
disturbances, and fluctuations), and treatment of one or
more of these clinical features may exacerbate existing
symptoms or produce new ones. The heterogeneity of
LBD symptoms and presentations not only make a uni-
form standard of care difficult, but also underlie some
clinical trial design challenges regarding study focus,
subject criteria, and outcome measures.
Current state of clinical trials in LBD
Despite the emphasis in NIH ADRD recommendations
and increased numbers of clinical trials for LBD in re-
cent years, randomized controlled trials in LBD lag be-
hind those conducted in other neurodegenerative
diseases (e.g., AD, non-demented PD), do not yet ad-
dress the full range of LBD symptoms, and primarily
focus on symptomatic rather than disease-modifying
therapies. Several reviews discuss recent clinical trials in
LBD [4, 5, 22, 24, 27]. In one review of DLB trials listed
in ClinicalTrials.gov from 2002 to 2019, there were 87
registered trials, and of those, 30 trials studied pharma-
cological agents or devices [5]. There were 9 pharmaco-
logical agents and one device studied in 22 trials. Most
trials were phase 2 or post-marketing or exploratory
studies with a smaller number of phase 2/3 or pilot de-
vice studies. All focused on cognition, psychosis, or sleep
symptoms, and one trial focused on motor symptoms.
Fewer than 10 trials in LBD have been completed be-
tween 2016 and 2020, and recent/ongoing LBD trials re-
main largely focused on cognitive outcomes but may
utilize novel or repurposed agents (Table 1). To date, no
trials have studied fluctuations, dysautonomia, agitation,
or apathy in LBD.
Optimizing clinical trial design in LBD (Table 2,
Fig. 1)
Study population
Fundamental considerations for LBD trials include
whether to combine DLB and PDD participants in the
same trial or to conduct separate trials for DLB and for
PDD. Despite shared clinical, neurobiological, and
pathological features, DLB and PDD groups may demon-
strate differing treatment responses. DLB patients receiv-
ing memantine showed greater improvement on AD
Cooperative Study-Clinical Global Impression of Change
(ADCS-CGIC) scores than those receiving placebo, but
the PDD group failed to show benefit vs. placebo; add-
itionally, the DLB, but not the PDD, group showed sig-
nificant improvement on Neuropsychiatric Inventory
(NPI) scores [28]. AD co-pathology represents an im-
portant source of clinically meaningful biological hetero-
geneity in LBD phenotype and may influence clinical
response. The development of biomarkers and clinical-
pathological correlations are needed to help separate
clinical differences between PDD and DLB from under-
lying biological differences.
Defining the LBD trial population requires decisions
regarding which definitions and diagnostic criteria to
use. To date, trials have primarily utilized DLB consen-
sus criteria (3rd revision) [29] and the DSM-IV-TR for
PDD. Very few trials have used the 2007 PDD criteria,
and some trials utilize ranges or cutoff scores for the
Mini-Mental State Examination (MMSE), Clinical De-
mentia Rating Scale, or Montreal Cognitive Assessment
for enrollment [14]. Study criteria often do not specify
the inclusion of probable vs. possible DLB. Defining
PDD by DSM criteria may bias towards amnestic pheno-
types, which may potentially reflect greater underlying
AD co-pathology, and thus, influence treatment effects
[30]. In LBD clinical trials, inclusion criteria have been
based on clinical features rather than adjunctive bio-
markers. In contrast, in some PD clinical trials, dopa-
mine transporter scans are incorporated, and imaging
and biofluid markers are commonly utilized in clinical
trials for AD and the MCI stage of AD. With growing
interest in disease-modifying strategies or symptomatic
therapies for milder or earlier stages, how to best design
trials for prodromal or MCI stages of PD (PD-MCI) or
DLB (MCI-LB) merits consideration. While several trials
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have been conducted in PD-MCI, operationalization of
MCI-LB research criteria is just beginning [17, 31–33].
Regarding the broad range of LBD symptomatology,
the cognitive phenotype includes attentional, executive
function, and visuospatial deficits, but memory and
naming may also be affected in a subset of patients.
Some LBD patients have greater neuropsychiatric, auto-
nomic, or sleep phenotypes, and a subset of people with
DLB do not have parkinsonism. Trials focusing on cog-
nitive endpoints may not capture other LBD core or
supportive features. Some trials specifically exclude
major depression or capture additional LBD symptoms
only in secondary or exploratory endpoints (e.g., NPI,
Unified PD Rating Scale [UPDRS] Part 3). Detailed
descriptions of core and supportive features in LBD trial
participants are often lacking. One exception is the DLB
donepezil trial by Mori et al. in which frequencies of
core features were provided, along with details of sug-
gestive and supportive features [34]. Co-morbidities such
as cerebrovascular disease are variably described in LBD
trials; such data were provided in the clinical trial for
memantine but not rivastigmine [28, 35]. Concomitant
medications frequently used in LBD (e.g., cholinesterase
inhibitors, dopaminergic medications, antidepressants,
and antipsychotics) also vary in how they are handled in
study design. Some studies exclude LBD participants
taking these medications, whereas others demonstrate
variable rates of use, which potentially could influence
Table 1 Selected recent/ongoing and completed LBD clinical trials 2016–2020
ClinicalTrials.gov
identifier
Population Drug/
intervention
Mechanism Trial
design
Primary outcome Results for primary
outcome
NCT03305809 DLB or PDD Mevidalen D1 positive allosteric
modulator (D1PAM)
Phase 2,
DB-PC
CDR computerized cognition
battery continuity of attention
composite score
Ongoing
NCT03413384 PDD Ceftriaxone Glutamatergic activity,
excitotoxicity reduction
Phase 2,
DB-PC
ADAS-Cog Ongoing
NCT02914366 PDD Ambroxol Raise beta-Gcase, lower α-
synuclein
Phase 2,
DB-PC
ADAS-Cog, ADCS-CGIC Ongoing
NCT03774459 PDD Anavex2-73 Cellular homeostasis
restoration via sigma-1
and muscarinic receptors
Phase 2,
DB-PC
CDR computerized cognition
battery continuity of attention
composite score, safety
Ongoing
NCT03713957 PDD or PD-
MCI
GRF6021 Plasma-derived product Phase 2,
DB-PC
Safety Ongoing
NCT03467152 DLB E2027 Selective phosphodiesterase
inhibitor type 9
Phase 2,
DB-PC
MoCA, CIBIC+ Ongoing
NCT04002674 DLB Nilotinib Tyrosine kinase inhibitor Phase 2,
DB-PC
Safety, tolerability Ongoing
NCT02669433 DLB Intepiridine 5HT-6 antagonist Phase 2,
DB-PC
UPDRS Part 3 Negative
NCT01023672 DLB Armodafinil Unknown Open-label,
pilot
ESS, MWT Positive
NCT01340001 DLB DBS of nucleus
basalis of
Meynert
Neuromodulation Open-label,
pilot
Free recall on FCSRT Completed no results
yet
NCT02258152 PDD SYN120 5HT-6/5HT-2A antagonist Phase 2,
DB-PC
CDR computerized cognition
battery continuity of attention
Negative
NCT01701544 PDD DBS of nucleus
basalis of
Meynert
Neuromodulation Open-label,
pilot
Abbreviated cognitive battery,
safety
Safe but no cognitive
improvement
NCT02640729 DLB or PDD
with VH
Nelotanserin 5HT-2A antagonist Phase 2,
DB-PC,
cross-over
Safety, UPDRS Part 3 Safe/well tolerated but
no significant changes
on endpoints
NCT03325556 DLB or PDD
with
psychosis
Pimavanserin 5HT-2A inverse agonist/
antagonist
Phase 3,
time to
event
Time to relapse Positive
NCT02708186 DLB or PDD
with RBD
Nelotanserin 5HT-2A antagonist Phase 2,
DB-PC
RBD frequency Negative
Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale-Cognitive Subscale, ADCS-CGIC AD Cooperative Study-Clinical Global Impression of Change, CIBIC+
Clinician’s Interview-Based Impression of Change plus Caregiver Input, DB-PC double-blind, placebo controlled, DLB dementia with Lewy bodies, ESS Epworth
Sleepiness Scale, FCSRT Free and Cued Selective Reminding Test, LBD Lewy body dementia, MoCA Montreal Cognitive Assessment, MWT Maintenance of
Wakefulness Test, PDD Parkinson’s disease dementia, RBD REM sleep behavior disorder, UPDRS Unified Parkinson’s Disease Rating Scale, VH visual hallucinations
Goldman et al. Alzheimer's Research & Therapy          (2020) 12:137 Page 4 of 11
outcomes and generalizability of findings. In memantine
trials, cholinesterase inhibitors were excluded by Emre
et al., but allowed by Aarsland et al. with their use in
47% of drug and 63% of placebo groups [28, 36]. Future
trials may benefit from addressing a range of LBD symp-
toms, considering subgroups of LBD based on pheno-
types, biomarker profiles, or genotype, as well as
accounting for co-morbidities or co-pathologies that
may influence cognitive status.
Recruitment and retention
Recruitment and retention of study subjects are well-
known challenges of clinical research, in general and in
LBD. Subjects meeting criteria for many studies are
often younger, male, healthier, wealthier, and more likely
Caucasian, which may limit generalizability of findings.
The study cohort in the Dubois et al. trial of donepezil
in PDD, recruiting from 13 countries in Europe, plus
Russia, South Africa, Australia, New Zealand, and
Canada, was represented by 98% White, 1% Black, and
1% other [37]; similar demographics (98–100% White)
are found in the LBD memantine and rivastigmine trials
involving multiple European countries [28, 35]. Strat-
egies for minority recruitment in LBD trials are needed.
Subject retention and study completion can be difficult,
with completion rates of about 70–80% in several LBD
trials. These aspects can be particularly challenging
when trials involve older participants with dementia, be-
havioral, and motor issues; assessment batteries are long
and complex; procedural burden (blood draws, lumbar
punctures, imaging) is high; and logistic issues (e.g.,
transportation, lodging, financial, fatigue) pose chal-
lenges. LBD caregivers, who also provide data for clinical
trials, often face high degrees of burden and stress. Part-
nerships with patient advocacy groups and foundations
for registries and awareness provide opportunities to
help with study recruitment [38]. Considerations for
transportation, televisits, or home monitoring may re-
duce barriers of study enrollment and retention [39, 40].
Primary outcome measures
Determining primary outcome measures for LBD clinical
trials include critical decisions such as whether to have a
single primary or a co-primary outcome measure and
whether to incorporate functional outcome measures or
psychosocial aspects such quality of life or caregiver bur-
den. These decisions may depend on the trial’s focus—
symptomatic treatment vs. disease modification, certain
clinical features, safety, tolerability, time to event, sur-
vival, phase of the trial (e.g., phase 1–4), and design (e.g.,
open label; double-blind, placebo-controlled trial; or
other). Studies for approval of AD drugs typically have
Table 2 Barriers and challenges to developing clinical trials in Lewy body dementia
Category Barriers and challenges
Trial focus - Need for both disease-modifying and symptomatic trials
- Lack of studies focusing on the breadth of LBD symptoms, including non-cognitive outcomes
Study population - Delays in LBD diagnosis
- Heterogeneity of clinical symptomatology
- Co-morbidities (e.g., cerebrovascular disease)
- Concomitant medication use (e.g., cholinesterase inhibitors, antipsychotics, parkinsonian
medications)
Recruitment and retention - Cognitively impaired population
- Lack of under-represented minorities in studies
- Complex and long assessment batteries
- Study procedures (e.g., lumbar puncture, imaging)
- Caregivers with high degrees of burden and stress
- Long travel distances to study centers
- Retention of older adults with combined cognitive, behavioral, and motor symptoms
Selection of outcome measures - Lack of LBD-specific outcome measures
- Existing outcome measures designed more for use in AD trials
- Optimal outcome for different symptoms is uncertain
- Existing outcome measures often lack validated measurement properties for LBD
(e.g., inter-rater reliability, sensitivity to change)
Study execution - Medication effects on attention and alertness
- Cognitive fluctuations, which may affect test performance
- “On” and “off” timing in individuals with Parkinson’s disease
Biomarkers - Lack of biomarkers of progression
- Lack of established α-synuclein biomarkers (imaging, biofluid)
- Biomarkers in DLB criteria focus on diagnosis rather than clinical trial use
- Lack of biomarker standardization
- Lack of availability or access to some biomarker studies (e.g., dopaminergic imaging,
polysomnography, cardiac MIBG)
Abbreviations: AD Alzheimer’s disease, LBD Lewy body dementia
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used a co-primary approach to assess global cognitive
and functional measures. In 2018, the US FDA issued a
new guidance that recognized the challenges in this ap-
proach, particularly for early stages of dementia, where
drugs may target disease states prior to the onset of
overt dementia [41]. This guidance proposed that for
those with early stage AD, sensitive neuropsychological
tests could be used as a primary endpoint to provide ad-
equate support for drug approval, and some trials could
utilize a time to event model for clinically meaningful
events. Application of these guidances in LBD trial de-
sign awaits exploration and may carry relevance for tar-
geting early stages of LBD including idiopathic RBD,
MCI-LB, or PD-MCI [16, 17].
Primary endpoints of LBD trials, to date, have largely
been AD-centric. Large, double-blind randomized trials for
donepezil and rivastigmine in PDD used the AD Assess-
ment Scale-Cognitive Subscale (ADAS-Cog) as the primary
endpoint with the co-primary endpoint of the Clinician’s
Interview-Based Impression of Change plus Caregiver In-
put (CIBIC+) or ADCS-CGIC, respectively [35, 37]. Two
LBD memantine trials utilized the ADCS-CGIC [28, 36].
The MMSE and CIBIC+ were the primary endpoints in
the randomized controlled trial of donepezil in DLB [34],
and in another study, with the co-primary of the NPI-2
subscale for hallucinations and fluctuations, which has not
been validated as an outcome measure in this form [42].
Several recent or ongoing trials in LBD utilize the Cogni-
tive Drug Research (CDR) Computerized Assessment Sys-
tem, mainly attention scores (NCT03358253 with SYN120,
NCT03305809 with LY3154207) [43].
Few LBD clinical trials have examined visual hallucina-
tions, sleep (RBD, hypersomnolence), and motor signs of
parkinsonism. Trials for autonomic symptoms, mood
disorders, or fluctuations in LBDs are lacking. For those
LBD studies of psychosis, primary endpoints vary from
motor function (nelotanserin, NCT02640729), time to
relapse of psychosis (pimavanserin, NCT03325556), and
the NPI-psychosis subscale (MP-101, NCT03044249). A
trial of nelotanserin for LBD-related RBD assessed RBD
frequency (NCT02708186), and in an open-label, pilot
study of armodafinil for hypersomnolence in DLB, pri-
mary efficacy measures were the Epworth Sleepiness
Score and Maintenance of Wakefulness Test [44]. Stud-
ies of zonisamide in DLB for parkinsonism utilized the
UPDRS Part 3 as the primary endpoint [45, 46].
Opportunities for LBD trial design include having end-
points and measures validated in LBD and that meet
regulatory agency clinical trial qualifications. Such mea-
sures could be developed through data mining from lon-
gitudinal observational studies and clinical trials or from
new or modified assessment instruments with appropri-
ate psychometric properties for LBD. This will allow for
modeling of effect size and appropriate duration of trials,
both of which are critical for power estimates.
Assessments
Testing for cognitive impairment for LBD trials requires
properly validated measures, with strong test-retest reli-
ability, sensitivity to the type of deficits and spectrum of
cognitive impairment/dementia in LBD, and robust
Fig. 1 Considerations and an example for optimizing LBD clinical trial design. CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; LBD, Lewy
body dementia; MCI, mild cognitive impairment; PDD, Parkinson’s disease dementia
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normative data. Decisions about cognitive test batteries
need to consider global vs. specific domain assessments,
length, burden, fatigue, fluctuations, and motor demands
as well as floor and ceiling effects. Study design may fac-
tor in use of composite scores, measures of global cogni-
tion, and controlling for motor effects, even with
computerized tests [47, 48].
While scales to elicit neuropsychiatric and auto-
nomic features, collectively or individually, exist in
the PD arena, validation in LBD is lacking. Trials
must either focus only on selected features or balance
the need to be comprehensive using a variety of dif-
ferent scales while minimizing potential study burden.
Parkinsonism has typically been measured by the
UPDRS Part 3 or MDS-UPDRS Part 3, but these clin-
ical measurements do not fully capture the sensitivity
and type of motor symptoms (e.g., gait, balance, falls)
in LBDs or everyday motor function at home. Oppor-
tunities to assess motor features and response to
intervention in broader, more continuous, and real-
life environments may include use of quantitative
measures and remote assessment with wearable sen-
sor technology [49, 50].
Fluctuating cognition and alertness are core features in
LBD that have the potential to greatly influence study out-
comes, remain poorly understood, and are challenging to
measure. To date, there are no established methods by
which to account for DLB fluctuations in clinical trials,
though several clinical scales, electrophysiological or im-
aging studies, or reaction time measurements may provide
opportunities to assess this [51, 52]. Test performance at
study visits may be affected by cognitive or physical fa-
tigue, medications that alter attention and alertness, co-
morbid psychiatric symptoms, orthostatic hypotension,
and “on and off” timing in those with PD. Longitudinal
data from observational studies and multiple data points
obtained in interventional studies may help address these
concerns and detect patterns of performance.
Biomarkers and genetics
Biomarkers in LBD, whether neuroimaging (molecu-
lar, structural, functional), fluid-based (blood,
cerebrospinal fluid [CSF], urine, or other), or elec-
trophysiological, as well as genetic subtypes of LBDs
have the potential to be used in research for patient
selection, outcome measures, and target engagement
[53]. Biomarkers in the DLB criteria aid in diagnosis
and distinction from AD, though these biomarkers
vary in their availability for clinical and research use
[29]. For PDD diagnosis, the use of biomarkers re-
mains limited to research. Several proteins have been
investigated as biomarkers for LBD, including α-
synuclein, amyloid-β, and tau, as measured by
molecular imaging and biofluids and representing
indirect measures of underlying neurodegeneration
and pathology. While dopamine transporter scanning
has been utilized in some PD trials for inclusion cri-
teria, these scans have not been incorporated into
LBD trials for patient selection [54]. Use of dopa-
mine transporter imaging in early LBD (e.g., MCI-
LB) also awaits further study. Stratifying LBD pa-
tients in clinical trials by dopaminergic imaging re-
sults may not be a simple decision as this may
introduce bias towards more parkinsonian pheno-
types of LBD. The lack of α-synuclein imaging re-
mains a major gap in the field. Although amyloid-β
PET imaging reveals that about 30–50% of people
with LBD have positive scans, the frequency of posi-
tive tau imaging may be lower [55, 56]. This adds to
the pathologic heterogeneity of LBD, since AD co-
pathology is present in about 50% of autopsied LBD.
Moreover, there is evidence of a dose-dependent as-
sociation with survival [57]. Amyloid-β and tau bio-
markers have potential diagnostic utility in LBD
trials by allowing for subgroup stratification (e.g.,
LBD with or without co-existing AD) as well as in
target engagement for disease-modifying trials. Bio-
marker profiling approaches in LBD would be greatly
enhanced by having robust markers of α-synuclein
pathology.
CSF measures of amyloid-β 1-42 (AB42), tau, and
phosphorylated-tau have been associated with worse
cognitive outcomes in some LBD studies [53]. CSF bio-
markers, including α-synuclein and amyloid-β, could
be used for study entry criteria and target engagement
in LBD trials, though inclusion of lumbar punctures
may affect subject enrollment and retention. One chal-
lenge is the high degree of variability in biomarker fluid
assays including CSF; inter-laboratory variability for as-
says of α-synuclein is about 10% (range 5–20%) [58].
Thus, standardizing fluid analyses is essential. Longitu-
dinal data for many of these biomarkers as well as
comparisons between DLB and PDD, and among sub-
groups or at-risk cohorts (e.g., RBD, MCI), are crucial.
Incorporation of amyloid-β biomarkers (imaging and/
or CSF) into inclusion criteria is already underway in
AD trials, as are trials of anti-amyloid therapeutics [59,
60]. In LBD, one study of memantine incorporated bio-
markers, finding that some PDD receiving drug and
having high homocysteine levels responded signifi-
cantly better [61]. Opportunities include partnerships
between AD and LBD biomarker efforts, data and sam-
ple sharing (e.g., federal- and foundation-funded pro-
grams), development and continued follow up of well-
characterized clinical cohorts with biomarker samples
(e.g., PD Biomarker Program, Parkinson’s Progression
Markers Initiative, NIA AD Centers, DLB consortium),
and autopsy studies.
Goldman et al. Alzheimer's Research & Therapy          (2020) 12:137 Page 7 of 11
EEG is recognized as a supportive biomarker in the
diagnosis of DLB, with prominent posterior slow-wave
activity with periodic fluctuations in the pre-alpha/theta
range [13]. Quantitative or visually assessed EEG differ-
entiates DLB from AD with high sensitivity and specifi-
city and may correlate with cognitive changes,
fluctuations, and hallucinations in DLB [62, 63]. EEG
also may have a role not only in diagnosing MCI-LB,
with slower frequencies in pre-alpha and theta ranges
compared to healthy controls and intermittent delta ac-
tivity patterns differentiating MCI-LB from MCI-AD,
but also in predicting conversion from MCI-LB to DLB
[64, 65]. While potentially less costly and less invasive
than some biomarker studies, use of EEG as a diagnostic
or prognostic biomarker for LBD will require increased
standardization, understanding of inter-individual vari-
ability, integration with imaging and biofluid markers,
and larger-scale prospective studies.
Genetic risk factors for both AD and PD may con-
tribute to the development and symptoms of LBD.
Some genetic mutations or polymorphisms (e.g.,
APOE locus, MAPT, and GBA genes) may influence
the presence and severity of cognitive impairment in
LBD [66–68]. APOE e4 carrier status has been linked
to greater cognitive impairment and co-existing AD
pathology in LBD [57, 67, 68]. To date, these genetic
markers have not been utilized in LBD trials. In
contrast, AD/MCI trials have incorporated genetic
mutations (e.g., dominantly inherited AD) or poly-
morphisms (APOE e4 alleles) into trial design. GBA
mutations, a susceptibility factor for PD, are found
in those with DLB and LBD with AD pathology to a
greater degree than in AD or control participants
[67]. Trials targeting GBA carriers in PD are emer-
ging [69]. In addition, GBA may play a role in target
engagement for trials. Ambroxol is currently under
study in a phase 2 trial of PDD (NCT02914366),
examining its effect on the ADAS-Cog and CGIC,
with additional measures of MRI, CSF, and Gcase
activity in lymphocytes [70].
Conclusions
In summary, there are challenges but also opportunities
for clinical trials in LBD. Advances in our understanding
of LBD symptomatology, diagnoses, prodromal stages,
longitudinal changes, and pathophysiological mecha-
nisms will enable us to discover new targets and strat-
egies for therapeutic interventions. This approach will
enable us to define more biologically homogenous
groups of LBD patients for inclusion criteria that can
improve efficiency of trials, especially those targeting
specific underlying disease mechanisms for α-synuclein
and/or AD neuropathology. Defining trial focus areas
with input from the LBD patient community, along with
implementing outcome measures validated in LBD; com-
prehensive, but not burdensome, test batteries; and bio-
markers reflecting key mechanisms of disease are future
goals of LBD trials. Mock clinical trials, as performed in
frontotemporal lobar degeneration, may provide insight
into disease progression and optimal outcome measures
[71]. Observational clinical research in PD, PDD, and
DLB with harmonized assessments, brain donation for
research, and data and biosample sharing are critical.
Partnership and consultation across patients, clinicians,
researchers, industry, and government agencies on trial
design and regulatory guidance regarding FDA will be
vital for the future of LBD trials.
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